Business
Citius Pharmaceuticals Selected to Receive Best Poster Award at the International Society for Cell and Gene Therapy 2021 Annual Meeting
Poster highlighting proof-of-concept study of Citius' iPSC-derived stem cell therapy in acute lung injury chosen for Best Poster Award at ISCT 2021 from among
About this update from Citius Pharmaceuticals, Inc.
[{"type":"text","content":"Poster highlighting proof-of-concept study of Citius' iPSC-derived stem cell therapy in acute lung injury chosen for Best Poster Award at ISCT 2021 from among 336 posters selected from,400 abstracts submitted\n\n\nCRANFORD, N.J., May 25, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. (\"Citius\" or the \"Company\") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a focus on anti-infective products in adjunct cancer care, unique prescription products and stem cell therapy, today announced that it has received the Best Poster Award at the prestigious International Society for Cell and Gene Therapy (ISCT) 2021 Annual Meeting. \nThe poster, titled \"Novel Induced-Mesenchymal Stem Cells (i-MSCs) Attenuate Severity of ARDS in Septic Sheep,\" will be presented today, May 25, 2021 by Dr. Perenlei Enkhbaatar, Professor and Director of the Translational Intensive Care Unit at The University of Texas Medical Branch. \n\"The ISCT annual meeting brings together the brightest minds in cell and gene therapy and highlights cutting edge research in the field,\" stated Dr. Myron Czuczman, Chief Medical Officer and Executive Vice President of Citius. \"We are honored to be selected for the Best Poster Award from among this distinguished peer group. The interim results demonstrate a marked improvement in i-MSC treated animals over control animals in key clinical parameters including: improved oxygenation, less systemic shock, and reduced bacterial burden and vascular injury to the lungs. We are encouraged by the data and welcome the support and engagement of the scientific research community,\" concluded Dr. Czuczman.\nMyron Holubiak, President and Chief Executive Officer of Citius added, \"We are grateful to be recognized by our peers for this award as we advance our novel stem cell program for the treatment of ARDS. In parallel to the expansion of our proof-of-concept ARDS sheep study, we are following guidance from the U.S. Food and Drug Administration (FDA) in the development of a cGMP Master Cell Bank of i-MSCs. I am pleased to report that we have completed the development of an i-MSC Accession Cell Bank (ACB) which is to serve as the basis for a scalable cGMP compliant manufacturing capability to support all of our planned pre-clinical and clinical ...